BioLargo Wins Octane HTA Award for COVID-19 Response

Over the past few months, BioLargo pivoted to develop and deliver solutions to help combat the COVID-19 pandemic, including Clyraguard Personal Protection Spray, manufactured and sold by our subsidiary Clyra Medical Technologies. At the outset of the pandemic, we recognized that our iodine-based technologies would make a meaningful contribution to the fight against SARS-CoV-2 (the virus that causes COVID-19). Our response is directly in line with our mission statement to “make life better” because nothing is more important right now than helping protect people against this virus.

Last week at the 27^th Octane High Tech Awards, BioLargo was honored for its contribution to the fight against COVID with a “COVID-19 Response Recognition Award”. We thank the Octane team for this honor, and we are humbled to have been recognized among such incredible Orange County based innovators.

The award highlighted BioLargo’s agile response to COVID. They noted that the company’s subsidiary Clyra Medical Technologies worked quickly to roll out Clyraguard Personal Protection Spray (www.clyramedical.com/clyraguard), which recently launched to great enthusiasm, with sales and distribution presently ramping up through national partners.

Clyraguard, an FDA-registered hospital-grade disinfectant, offers an additional line of defense against COVID-19. It helps protects mask-wearers from cross contamination by providing quick, safe, effective on-the-go decontamination of masks and other noncritical PPE. It has been tested and proven effective to completely inactivate SARS-CoV-2 (COVID-19) in a published study conducted by Galveston National Lab (UTMB-Galveston), and it is proven to be non-toxic, non-irritating, non-sensitizing, safe on skin, and eco-friendly.

Launching this product was no easy task – Clyra set up contract manufacturing capable of delivering up to 1 million units per month, secured FDA registration, built a full-scale marketing campaign that is currently launching, and established partnerships with national distributors.

BioLargo also advanced its proprietary iodine technology to be used as an environmental disinfectant. Already, third-party studies were conducted that proved the product, derived from BioLargo’s CupriDyne® technology, achieving complete inactivation against SARS-CoV-2 in only 10 minutes.

This award is not the first time that BioLargo has been honored by Octane at their HTA event. In 2017, BioLargo received an Octane award for Horizontal Disruption because of the company’s diverse innovative life sciences technologies. The following year, BioLargo CEO Dennis P. Calvert was invited to be a judge for the 2018 HTA awards alongside decorated entrepreneur Shawn Dougherty (who is now Clyra Medical Technologies’ Chief Revenue Officer). We believe organizations like Octane, which is Orange County's premier tech incubator, are crucial in times like these, as they promote the advancement of critically important innovative technologies that help make people’s lives better.

On a Clyraguard-related note – we are anxious to update everyone on the advancement of Clyraguard sales, so keep an eye out for more Clyraguard news!

BioLargo’s CupriDyne Technology Shown Capable of Complete SARS-CoV-2 Inactivation in 10 Minutes

Westminster, CA – September 2, 2020 – BioLargo, Inc. (OTCQB:BLGO), developer of sustainable technologies and a full-service environmental engineering company, today announced an important milestone in its ongoing efforts to bring to market a safe and effective antiviral disinfectant based on its patented CupriDyne® technology. In a third-party study conducted by researchers at the Galveston National Laboratory (GNL) at the University of Texas Medical Branch (UTMB), a modified CupriDyne formula was shown to cause complete inactivation of SARS-CoV-2 (the COVID-19 virus) in 10 minutes – roughly the same performance observed with highly concentrated bleach.

BioLargo had previously disclosed that its CupriDyne technology was proven capable of reducing SARS-CoV-2 titers by 99% after 30 minutes, with complete inactivation occurring after 60 minutes of CupriDyne exposure. Since that time, BioLargo scientists worked to modify the CupriDyne formula to achieve faster bacterial and viral inactivation in order to prepare to file for an EPA registration for a new disinfecting product (to be named) that is based on the CupriDyne technology. These new results indicate that those efforts were successful, and that the technology is now capable of total antiviral disinfection in 10 minutes against SARS-CoV-2.

BioLargo President & CEO Dennis P. Calvert commented, “We believe that the future is bright for our CupriDyne-based disinfectants. We intend to apply for registration with the EPA once product designs are finalized.  It is important to understand that we are achieving these extraordinary results at a significantly lower concentration than that of bleach in the same test protocol. We have retained a leading EPA consulting firm to lead us in the EPA registration process and intend to move ahead as soon as possible. These products are a great addition to our expanding portfolio.”

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

About Galveston National Laboratory/UTMB

The Galveston National Laboratory (GNL) is a sophisticated high containment research facility that serves as a critically important resource in the global fight against infectious diseases. The GNL is located on the campus of the University of Texas Medical Branch and operates under the umbrella of UTMB’s Institute for Human Infections and Immunity.

Researchers at the GNL are internationally known for their expertise working with pathogens including Ebola and Marburg, emerging infectious diseases like MERS, and mosquito borne viruses like Zika and Chikungunya. The Galveston National Laboratory is home to research that is funded by NIAID, the U.S. Department of Defense, the U.S. Centers for Disease Control & Prevention and other federal agencies, as well as academic partners, private foundations, and the Biopharmaceutical industry.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

During the course of the stockholder presentation, BioLargo may make “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, regarding future events or the future financial performance of the company that are subject to change. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.